Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Abstract: Technical fields of building external wall decoration and material manufacturing, providing a mildewproof and antirot high-strength cement particle board and a preparation method thereof. The preparation method includes: (1) sequentially carbonizing and water-washing a shaving, and mixing the obtained carbonized shaving with a cement gelling agent, a curing agent aqueous solution and water to obtain a mixture; (2) molding the mixture to obtain a pre-molded material; and (3) sequentially curing and drying the pre-molded material to obtain the mildewproof and antirot high-strength cement particle board. Compared to ordinary cement particle board, which is not subjected to carbonization treatment and water-washing, the cement particle board of the present invention can effectively avoid mildew and rot, and can significantly improve the mechanical strength and durability thereof, helping to extend the service life of the cement particle board.

Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 µm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75: 1 or less, or about 0.50: 1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Abstract: A solenoid valve includes a main valve, a first auxiliary valve, a second auxiliary valve, a main valve body, and an auxiliary valve body. The main and auxiliary valve bodies are axially parallel and detachably connected. The main valve is mounted on the main valve body, the first and second auxiliary valves are mounted on the auxiliary valve body, which is provided with an air inlet, a cylinder port and an air discharging port. The air inlet communicates with the main valve through a first air passage. The cylinder port is sequentially in communication with the first and second auxiliary valves and the main valve through a second air passage. The air discharging port sequentially communicates with the first and second auxiliary valves and the main valve through a third air passage. The main and second auxiliary valves are solenoid valves. The first auxiliary valve is a hand-operated valve.

Abstract: The present invention discloses a method for quick hot-press forming of laminated wood. The method includes: drying a machined small wood material to a moisture content of 5-8 wt %; gluing the dried small wood material, and assembling and laying the dried small wood material to be a square material or a sheet material, where an adhesive for the gluing is a water-soluble adhesive having a solid content of 45-60 wt %; clamping the square material or the sheet material through a three-dimensional metal clamp; sending the clamped square material or sheet material together with the clamp into a microwave heating machine for microwave heating to obtain a formed laminated wood, where the time from the gluing to the entry into the microwave heating machine is controlled to not exceed 15 min.

Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 ?m. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Abstract: A solenoid valve includes a main valve, a first auxiliary valve, a second auxiliary valve, a main valve body, and an auxiliary valve body. The main and auxiliary valve bodies are axially parallel and detachably connected. The main valve is mounted on the main valve body, the first and second auxiliary valves are mounted on the auxiliary valve body, which is provided with an air inlet, a cylinder port and an air discharging port. The air inlet communicates with the main valve through a first air passage. The cylinder port is sequentially in communication with the first and second auxiliary valves and the main valve through a second air passage. The air discharging port sequentially communicates with the first and second auxiliary valves and the main valve through a third air passage. The main and second auxiliary valves are solenoid valves. The first auxiliary valve is a hand-operated valve.

Abstract: Technical fields of building external wall decoration and material manufacturing, providing a mildewproof and antirot high-strength cement particle board and a preparation method thereof. The preparation method includes: (1) sequentially carbonizing and water-washing a shaving, and mixing the obtained carbonized shaving with a cement gelling agent, a curing agent aqueous solution and water to obtain a mixture; (2) molding the mixture to obtain a pre-molded material; and (3) sequentially curing and drying the pre-molded material to obtain the mildewproof and antirot high-strength cement particle board. Compared to ordinary cement particle board, which is not subjected to carbonization treatment and water-washing, the cement particle board of the present invention can effectively avoid mildew and rot, and can significantly improve the mechanical strength and durability thereof, helping to extend the service life of the cement particle board.

Abstract: Technical fields of building external wall decoration and outdoor furniture material manufacturing, providing a durable inorganic particle board and a preparation method and an application thereof. The preparation method includes: (1) mixing heat-vulcanized silicone rubber with an organic solvent to obtain a sealant solution; (2) mixing calcium chloride, sodium dodecyl sulfate and water to obtain a curing agent solution; (3) spraying the sealant solution on the surface of a shaving to mix with the curing agent solution, an inorganic adhesive and water to obtain a mixture; (4) sequentially laying and hot-pressing the mixture to obtain a pre-molded material; and (5) sequentially curing and drying the pre-molded material to obtain the durable inorganic particle board. The inorganic particle board prepared by the method of the present invention can be well applied to outdoor decoration and outdoor furniture manufacturing, has good durability and a long service life.

Abstract: The present invention discloses a method for quick hot-press forming of laminated wood. The method includes: drying a machined small wood material to a moisture content of 5-8 wt %; gluing the dried small wood material, and assembling and laying the dried small wood material to be a square material or a sheet material, where an adhesive for the gluing is a water-soluble adhesive having a solid content of 45-60 wt %; clamping the square material or the sheet material through a three-dimensional metal clamp; sending the clamped square material or sheet material together with the clamp into a microwave heating machine for microwave heating to obtain a formed laminated wood, where the time from the gluing to the entry into the microwave heating machine is controlled to not exceed 15 min.

Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 ?m. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 ?m. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 ?m. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 ?m. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Abstract: Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.

Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.